

# George A Stouffer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1537195/george-a-stouffer-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117  
papers

1,580  
citations

21  
h-index

38  
g-index

140  
ext. papers

2,050  
ext. citations

6.5  
avg, IF

4.67  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 117 | Application and interpretation of fractional flow reserve in heavily calcified coronary arteries <b>2022</b> , 61-69   |      |           |
| 116 | Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024159  | 6    | 1         |
| 115 | Bezold-Jarisch Reflex <b>2022</b> , 1, 100029  |      |           |
| 114 | Length of Preprocedure Fasting Was Associated With Contrast Associated-Acute Kidney Injury in High-Risk Patients Undergoing Coronary Angiography. <i>American Journal of Cardiology</i> , <b>2021</b> , 159, 1-7   | 3    |           |
| 113 | Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 6, 100172-100172   | 1.9  | 1         |
| 112 | Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 533-549 | 2.6  | 2         |
| 111 | Resting Pd/Pa correlates with fractional flow reserve but not angiographic severity in calcified coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 97, 625-631  | 2.7  | 0         |
| 110 | Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 705-715  | 6.1  | 8         |
| 109 | Ability of a novel shock index that incorporates invasive hemodynamics to predict mortality in patients with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, 87-94   | 2.7  | 1         |
| 108 | Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. <i>Hypertension</i> , <b>2021</b> , 77, 632-639   | 8.5  | 1         |
| 107 | Expression of Cyr61 in ApoE mice with chronic unilateral renal artery ligation. <i>Scientific Reports</i> , <b>2021</b> , 11, 3606   | 4.9  |           |
| 106 | An Update on Catheter-Based Renal Denervation for the Treatment of Hypertension. <i>Current Cardiovascular Risk Reports</i> , <b>2021</b> , 15, 1  | 0.9  |           |
| 105 | Patients with Left Ventricular Thrombus Despite Normal Systolic Function. <i>American Journal of the Medical Sciences</i> , <b>2021</b> , 362, 198-206   | 2.2  |           |
| 104 | Usefulness of a Novel Risk Score to Predict In-Hospital Mortality in Patients $\geq 60$ Years of Age with ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2021</b> , 154, 1-6   | 3    |           |
| 103 | Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 431-441   | 2.6  | 4         |
| 102 | Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , <b>2020</b> , 19, 333-352  | 64.1 | 82        |
| 101 | Left Ventricular Thrombus Formation in the Setting of Normal Systolic Function. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 1470-1474   | 1.2  | 1         |

|     |  |      |     |
|-----|--|------|-----|
| 100 | Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 485-490              | 3    | 6   |
| 99  | Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 239-252  | 2.1  | 6   |
| 98  | Effect of Gender on Clinical Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2020</b> , 13, 554-556                                 | 5.2  | 1   |
| 97  | Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 160-169  | 8.1  | 28  |
| 96  | Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in PCI. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1867  | 5    | 5   |
| 95  | Mechanisms of ST Elevation Myocardial Infarction in Patients Hospitalized for Noncardiac Conditions. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1393-1398  | 3    | 2   |
| 94  | Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 647-652 | 9.4  | 29  |
| 93  | Logistical Challenges Associated With Implementing Precision Medicine. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1300-1306   | 16.2 | 1   |
| 92  | CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2019</b> , 12, e002441   | 5.2  | 9   |
| 91  | Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. <i>Circulation</i> , <b>2019</b> , 139, 1047-1056  | 16.7 | 175 |
| 90  | In-Hospital ST-Segment Elevation Myocardial Infarction: Improving Diagnosis, Triage, and Treatment. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 527-531  | 16.2 | 15  |
| 89  | Correlation of infarct size with invasive hemodynamics in patients with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 92, E333-E340  | 2.7  | 4   |
| 88  | Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 726-732  | 9.4  | 11  |
| 87  | Ultrafine particulate matter exposure impairs vasorelaxant response in superoxide dismutase 2-deficient murine aortic rings. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , <b>2018</b> , 81, 106-115                  | 3.2  | 8   |
| 86  | Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 664-674   | 6.1  | 64  |
| 85  | Targeted repair of heart injury by stem cells fused with platelet nanovesicles. <i>Nature Biomedical Engineering</i> , <b>2018</b> , 2, 17-26  | 19   | 101 |
| 84  | Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e002069   | 5.2  | 41  |
| 83  | Impact of Type 2 Myocardial Infarction (MI) on Hospital-Level MI Outcomes: Implications for Quality and Public Reporting. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,  | 6    | 36  |

|    |   |      |     |
|----|---|------|-----|
| 82 | Causes and hemodynamic findings in chronic severe pulmonary regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , <b>2018</b> , 92, E197-E203  | 2.7  | 10  |
| 81 | Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 181-191   | 5    | 156 |
| 80 | Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1039-1046   | 2.6  | 18  |
| 79 | The use of hemodynamics to predict mortality in patients undergoing primary PCI for ST-elevation myocardial infarction. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 551-557  | 2.5  | 4   |
| 78 | Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2018</b> , 134, 24-31  | 3.7  | 9   |
| 77 | In-hospital outcomes after switching from a bivalirudin-first strategy to an unfractionated heparin-first strategy for percutaneous coronary interventions. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2018</b> , 8, 137-145  | 2.6  | 0   |
| 76 | Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 2148-2150   | 5.4  | 4   |
| 75 | Ratio of systolic blood pressure to left ventricular end-diastolic pressure at the time of primary percutaneous coronary intervention predicts in-hospital mortality in patients with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 90, 389-395 | 2.7  | 11  |
| 74 | Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 572-586  | 15.1 | 109 |
| 73 | CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1155-1166  | 2.6  | 24  |
| 72 | Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 2895-2911  | 5.8  | 18  |
| 71 | Angiographic severity does not correlate with fractional flow reserve in heavily calcified coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 226-232   | 2.7  | 7   |
| 70 | Identification of Factors Associated With Improved Survival After Renal Artery Stenting. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 664-668   | 3    | 5   |
| 69 | Hemodynamic Findings of Severe Subacute Aortic Regurgitation. <i>Journal of Invasive Cardiology</i> , <b>2017</b> , 29, E74   | 0.7  | 1   |
| 68 | Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1944-1954  | 2.2  | 23  |
| 67 | A Quality Improvement Program for Recognition and Treatment of Inpatient ST-Segment Elevation Myocardial Infarctions. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 1077-1079   | 16.2 | 6   |
| 66 | Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 109-19   | 6.3  | 41  |
| 65 | Hemodynamic and Intravascular Ultrasound Evaluation of an Infrarenal Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, e11-e12  | 5    |     |

|    |   |      |    |
|----|---|------|----|
| 64 | Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. <i>Nature Reviews Cardiology</i> , <b>2016</b> , 13, 148-54  | 14.8 | 14 |
| 63 | Effects of Restoration of Blood Flow on the Development of Aortic Atherosclerosis in ApoE-/- Mice With Unilateral Renal Artery Stenosis. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e002953                                  | 6    | 4  |
| 62 | Letter by Dai et al regarding article, "ST-elevation myocardial infarction diagnosed after hospital admission". <i>Circulation</i> , <b>2015</b> , 131, e6  | 16.7 | 2  |
| 61 | Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 303-13   | 2.6  | 27 |
| 60 | Pharmacological Therapy in the Management of Acute Coronary Syndromes <b>2015</b> , 517-531   |      |    |
| 59 | Is time of renal hypoperfusion an important variable in determining response to renal artery revascularization?. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 110   | 5    | 4  |
| 58 | Association of inpatient vs outpatient onset of ST-elevation myocardial infarction with treatment and clinical outcomes. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1999-2007                                     | 27.4 | 31 |
| 57 | Risk of developing coronary artery disease following a normal coronary angiogram in middle-aged adults. <i>Journal of Invasive Cardiology</i> , <b>2014</b> , 26, 624-8   | 0.7  | 2  |
| 56 | Acute ST-elevation myocardial infarction in patients hospitalized for noncardiac conditions. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000004  | 6    | 25 |
| 55 | Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. <i>Drugs</i> , <b>2011</b> , 71, 2009-30   | 12.1 | 21 |
| 54 | Influence of sex on the accuracy of oscillometric-derived blood pressures. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 112-9  | 2.3  | 6  |
| 53 | Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 2587-96        | 9.4  | 11 |
| 52 | Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction. <i>Drugs</i> , <b>2009</b> , 69, 1945-66   | 15.6 | 5  |
| 51 | Scintigraphic evidence of severe myocardial hypoperfusion in a patient with left anterior descending coronary artery bridging--case report and review of the literature. <i>American Journal of the Medical Sciences</i> , <b>2008</b> , 336, 498-502 | 2.2  | 3  |
| 50 | Hemodynamics of myocardial bridging. <i>Catheterization and Cardiovascular Interventions</i> , <b>2008</b> , 71, 590-3  | 2.7  | 5  |
| 49 | Hemodynamics of renal artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , <b>2008</b> , 72, 121-4  | 2.7  | 1  |
| 48 | Timing of surgery in aortic stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2006</b> , 8, 421-7  | 2.1  | 1  |
| 47 | Mechanical thrombectomy options in complex percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , <b>2006</b> , 68, 917-28  | 2.7  | 4  |

|    |   |      |    |
|----|---|------|----|
| 46 | A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. <i>American Heart Journal</i> , <b>2005</b> , 150, 1204-11   | 4.9  | 66 |
| 45 | Incidence and management of "no-reflow" following percutaneous coronary interventions. <i>American Journal of the Medical Sciences</i> , <b>2005</b> , 329, 78-85   | 2.2  | 9  |
| 44 | Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. <i>Catheterization and Cardiovascular Interventions</i> , <b>2005</b> , 66, 327-32 | 2.7  | 43 |
| 43 | Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1453-4, A12   | 3    | 3  |
| 42 | Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 61, 364-7   | 2.7  | 18 |
| 41 | Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. <i>Circulation</i> , <b>2003</b> , 107, 2914-9   | 16.7 | 60 |
| 40 | The Role of $\alpha\beta$ Integrins in Vascular Healing. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 187-193  | 7    | 44 |
| 39 | The role of alpha(v)beta3 integrins in vascular healing. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 87, 187-93   | 7    | 12 |
| 38 | Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. <i>Circulation</i> , <b>2001</b> , 104, 582-7  | 16.7 | 67 |
| 37 | Action Potentials3-6  |      |    |
| 36 | Atrial Flutter with 1:1 Conduction47-51   |      |    |
| 35 | Atrioventricular Nodal Re-Entry Tachycardia52-54  |      |    |
| 34 | Atrial Tachycardia59-60   |      |    |
| 33 | Brugada Syndrome61-63   |      |    |
| 32 | Complete Heart Block64-65   |      |    |
| 31 | Ventricular Tachycardia69-71  |      |    |
| 30 | Dextrocardia84-85   |      |    |
| 29 | Ventricular Septal Defect90-92  |      |    |

28 Aortic Insufficiency95-97

27 Pulmonic Stenosis98-100

26 Dilated Cardiomyopathy103-105

25 Normal Conduction and Complexes10-12

24 Anterior Myocardial Infarction112-114

23 Inferior-Posterior Myocardial Infarction115-119

22 Diagnosis of Myocardial Infarction with Existing Bundle Branch Block120-122

21 Pericarditis123-124

20 Pulmonary Embolus130-131

19 Electrodes and Leads13-16

18 Hyperkalemia135-137

17 Early Repolarization138-139

16 P-Pulmonale140-141

15 Digoxin Toxicity142-144

14 Atrial Myxoma145-146

13 Normal Rhythm and Rate17-21

12 Determining Axis and Intervals22-26

11 Effects of Electrolyte Abnormalities on ECG27-30

- 10 ECG Clues to the Presence of Hemodynamically Significant Congenital or Valvular Heart Disease in Young Adults31-37
- 9 Wolff-Parkinson-White Syndrome72-77
- 8 ECG Clues to the Presence of an Increased Risk of Sudden Cardiac Death in Young Adults38-45
- 7 Arrhythmogenic Right Ventricular Dysplasia109-111
- 6 Anatomy and Blood Supply of the Conduction System7-9
- 5 Long QT Syndrome66-68
- 4 Atrial Septal Defect Secundum79-81
- 3 Atrial Septal Defect Primum82-83
- 2 Intracerebral Bleed128-129
- 1 Introduction to ECG Interpretation1-2